Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01008527 · ClinicalTrials.gov registry record · Phase 1
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01008527 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 22 participants.
The verdict
NCT01008527, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what side effects CP 870,893 may cause when given with an immune stimulant called Oncovir poly IC:LC along with a melanoma vaccine. The CP 870,893, the Oncovir poly IC:LC and the melanoma vaccine are investigational drugs that have not been combined in patients before, and that have not been approved for sale by the Food and Drug Administration. The Oncovir poly IC:LC is intended to stimulate the body's immune system.
Interventions
- BIOLOGICAL Peptides
- DRUG CP 870,893
- BIOLOGICAL Oncovir poly IC:LC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01008527
The ClinicalTrials.gov registry entry for NCT01008527 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Peptides is the first listed.
NCT01008527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01008527 about?
NCT01008527 is a clinical study titled "Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100". The purpose of this study is to determine what side effects CP 870,893 may cause when given with an immune stimulant called Oncovir poly IC:LC along with a melanoma vaccine. The CP 870,893, the Oncovir poly IC:LC and the melanoma vaccine are investigational drugs that have not been combined in patie...
What is the current status of trial NCT01008527?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2009-10. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01008527?
The interventions under investigation include: Peptides (BIOLOGICAL), CP 870,893 (DRUG), Oncovir poly IC:LC (BIOLOGICAL).
Who is sponsoring clinical trial NCT01008527?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.